GNLX
GeneluxDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
GENELUX executes EU rollouts, avoids dilutive financing, and regulatory clarity accelerates adoption; revenue growth and better multiples re-rate the stock toward peers.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Commercial execution stalls, management raises equity on dilutive terms, or regulatory/reimbursement setbacks occur, compressing valuation below current levels.
Momentum
20
Value
41
Sentiment
58
Setup hits (3d)
— · Net —
AI TargetsBase $3.21 · Bull $4.17 · Bear $2.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-30 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net —
Target $17.50
Why
Momentum20 · Δ7d -
Value41 · Δ7d -0.1
Sentiment58 · Δ7d -
So what
Weak posture. Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
20
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
58
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 20.0 / Value 41.1 / Sentiment 57.5
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$128.69M
Beta
-
Shares Out
44.84M
P/E (TTM) · Derived
-3.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-4.04
Rev YoY
-100.0%
EPS YoY
-5.7%
Gross Margin
-6562.5%
Op Margin
-391575.0%
Net Debt
-$12.91M
Current Ratio
3.68
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology